Clinical and Translational Science Award
临床和转化科学奖
基本信息
- 批准号:10439923
- 负责人:
- 金额:$ 1016.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressCOVID-19 pandemicClinical ResearchClinical SciencesClinical Trials DesignClinical and Translational Science AwardsCollaborationsCommunitiesDentalElectronic Health RecordEnvironmentEvaluationEvolutionFacultyFoundationsGoalsHealthHealth BenefitHealth Care ResearchHealth systemHospitalsInfrastructureInstitutesInterdisciplinary StudyLaboratoriesLeadLeadershipLearningMedical centerMedicineMethodsMissionModelingNew YorkNew York CityPatientsPersonal SatisfactionPhasePhysiciansPresbyterian ChurchProblem SolvingProcessProgram DevelopmentPublic HealthPublic Health SchoolsRecording of previous eventsResearchResearch MethodologyResearch PersonnelResourcesSchool NursingSchoolsScienceSpeedStrategic PlanningStrategic visionSurgeonTimeTrainingTranslational ResearchUniversitiesVisionWorkforce Developmentbasecareercollegedissemination scienceeducation researchexperienceflexibilityimplementation scienceimprovedinnovationmeetingsmembernovelnovel therapeuticsoperationopioid epidemicprecision medicineprogramssuccesssynergismtranslational pipelineuser-friendly
项目摘要
Contact PD/PI: Reilly, Muredach P
OVERALL: PROJECT SUMMARY/ABSTRACT
Our mission is to improve the health of our patients and communities both locally and nationally through
innovations in clinical and translational research. Our strategic vision is to catalyze all phases of clinical and
translational science (T0-T4), synergize with our partners and stakeholders, and integrate activities within our
hub and across the national Clinical and Translational Science Award (CTSA) Program. To achieve this vision,
we will build on our strong established track-record (e.g., in precision medicine), our plans to tackle important
public-health challenges (e.g., COVID-19 pandemic, the opioid crisis) and to address critical barriers (e.g.,
innovation in use of electronic health records for research, clinical trial designs) as we embrace the CTSA
Program priorities designated in PAR-18-940. Our vision is to transform the health and wellbeing of our
communities in New York City, the nation and the world. To achieve this, we deploy our programs and resources
to develop, demonstrate and disseminate innovations in
clinical and translational science
across the full
translational spectrum.
As a comprehensive CTSA, we offer a broad array of support for trainees, scholars and
investigators across our entire hub which includes Columbia University, the Columbia University Irving Medical
Center, the New York Psychiatric Institute, and New York Presbyterian Hospital. At the same time, we move
flexibly and deeply to address critical scientific or institutional opportunities as well as major public health needs
and gaps. We achieve success by approaching our goals at multiple levels: a) Ongoing strategic planning
including an annual retreat to review operations and identify gaps, needs and opportunities; b) Monthly cross-
cutting “Theme” meetings to enable collaborative problem-solving in addressing gaps and opportunities; c) An
innovative Evaluation and Continuous Improvement strategy using participatory management to integrate
evaluation into program planning and execution; and d) A highly successful, innovative interdisciplinary training
and workforce development program built on a foundation of team science. Central to our efforts to improve
health and wellbeing at personal, community and national levels is our emphasis on strategic collaboration and
dissemination. Thus, we seek to continuously create and refine innovations for an integrated research- and user-
friendly translational research environment at our hub by: Harnessing partnerships across our entire hub;
Transforming collaborations with our local communities, the campus health system and across New York State;
And by accelerating bidirectional dissemination of innovative practices and learnings through collaborations with
the CTSA Program network and beyond.
Project Summary/Abstract Page 221
Contact PD/PI: Reilly, Muredach P
Narrative
The Clinical and Translational Science Award (CTSA) allows Columbia University to support novel programs
whose goal is to speed the transition from scientific discoveries made in the laboratory toward new therapies.
Building on our strong established track-record, we will tackle important challenges and critical barriers to
research. We will facilitate the training of scholars from diverse backgrounds underrepresented in translational
science who are knowledgeable about and available to focus on translational science later in their careers.
联系PD/PI: Reilly, Muredach P
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Muredach P Reilly其他文献
Single-cell multimodal profiling of monocytes reveals diverse phenotypes and alterations linked to cardiovascular disease risks
单核细胞的单细胞多模式分析揭示了与心血管疾病风险相关的多种表型和变化
- DOI:
10.1101/2024.02.18.580913 - 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Alexander C. Bashore;Chenyi Xue;Eunyoung Kim;Hanying Yan;Lucie Y. Zhu;Huize Pan;Michael D Kissner;Leila S Ross;Hanrui Zhang;Mingyao Li;Muredach P Reilly - 通讯作者:
Muredach P Reilly
1008-184 The effects of pravastatin and atorvastatin on markers of oxidant stress in vivo
- DOI:
10.1016/s0735-1097(04)91877-3 - 发表时间:
2004-03-03 - 期刊:
- 影响因子:
- 作者:
Bonnie Ky;Megan L Wolfe;Anne Burke;Philippe O Szapary;Muredach P Reilly;Jennifer B Dykhouse;Leanne T Bloedon;Garret A FitzGerald;Daniel J Rader - 通讯作者:
Daniel J Rader
Muredach P Reilly的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Muredach P Reilly', 18)}}的其他基金
Smooth muscle cell-derived cell fates and cellular interactions in atherosclerotic plaque stability in disease progression and regression.
平滑肌细胞衍生的细胞命运和细胞相互作用在疾病进展和消退中动脉粥样硬化斑块的稳定性。
- 批准号:
10567844 - 财政年份:2023
- 资助金额:
$ 1016.28万 - 项目类别:
Identification of smooth muscle cell genes causal in atherosclerotic plaque stability and cardiovascular disease risk
鉴定导致动脉粥样硬化斑块稳定性和心血管疾病风险的平滑肌细胞基因
- 批准号:
10720225 - 财政年份:2023
- 资助金额:
$ 1016.28万 - 项目类别:
Human LincRNAs in Macrophage Biology and Related Cardiometabolic Diseases
巨噬细胞生物学和相关心脏代谢疾病中的人类 LincRNA
- 批准号:
9402855 - 财政年份:2017
- 资助金额:
$ 1016.28万 - 项目类别:
Human LincRNAs in Macrophage Biology and Related Cardiometabolic Diseases
巨噬细胞生物学和相关心脏代谢疾病中的人类 LincRNA
- 批准号:
9983136 - 财政年份:2017
- 资助金额:
$ 1016.28万 - 项目类别:
Human LincRNAs in Macrophage Biology and Related Cardiometabolic Diseases
巨噬细胞生物学和相关心脏代谢疾病中的人类 LincRNA
- 批准号:
9531432 - 财政年份:2017
- 资助金额:
$ 1016.28万 - 项目类别:
相似海外基金
Depopulating Holding Centers during the COVID-19 Pandemic
COVID-19 大流行期间收容中心的人口减少
- 批准号:
2413624 - 财政年份:2024
- 资助金额:
$ 1016.28万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 1016.28万 - 项目类别:
Standard Grant
Return to work after the COVID-19 pandemic: a biopsychosocial perspective
COVID-19 大流行后重返工作岗位:生物心理社会视角
- 批准号:
24K16416 - 财政年份:2024
- 资助金额:
$ 1016.28万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Leveraging 'Positive Deviance' to improve learning under COVID-19 pandemic. A randomized intervention in rural East Africa
利用“正偏差”改善 COVID-19 大流行期间的学习。
- 批准号:
23K20687 - 财政年份:2024
- 资助金额:
$ 1016.28万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Leveraging an Existing Longitudinal Observational Cohort to Understand the Impacts of Cannabis Legalization and the COVID-19 Pandemic on Alcohol and Cannabis Use in At-risk Young Adults
利用现有的纵向观察队列来了解大麻合法化和 COVID-19 大流行对高危年轻人酒精和大麻使用的影响
- 批准号:
478397 - 财政年份:2023
- 资助金额:
$ 1016.28万 - 项目类别:
Operating Grants
Genomic Epidemiology of Methicillin-Resistant Staphylococcus aureus Infections Prior to and During the COVID-19 Pandemic
COVID-19 大流行之前和期间耐甲氧西林金黄色葡萄球菌感染的基因组流行病学
- 批准号:
494305 - 财政年份:2023
- 资助金额:
$ 1016.28万 - 项目类别:
Operating Grants
Fact-finding survey of nursing diagnoses, nursing outcomes, and nursing interventions in medical institution and edcational institution under COVID-19 pandemic
COVID-19大流行背景下医疗机构和教育机构护理诊断、护理结果和护理干预的实况调查
- 批准号:
23K09822 - 财政年份:2023
- 资助金额:
$ 1016.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Communities in Crises: The Dynamics of Social Resources for Resilience and Recovery in the Wake of the COVID-19 Pandemic
危机中的社区:COVID-19 大流行后社会资源的弹性和恢复动态
- 批准号:
ES/W00349X/1 - 财政年份:2023
- 资助金额:
$ 1016.28万 - 项目类别:
Research Grant
Impact of Different Learning Modalities on Science and Mathematics Teachers' Effectiveness and Retention during the COVID-19 Pandemic
COVID-19 大流行期间不同学习方式对科学和数学教师的有效性和保留率的影响
- 批准号:
2243392 - 财政年份:2023
- 资助金额:
$ 1016.28万 - 项目类别:
Continuing Grant
Did business support measures during COVID-19 pandemic create Zombie firms?: Evidence from Post-pandemic corporate performance
COVID-19 大流行期间的企业支持措施是否创造了僵尸公司?:大流行后企业绩效的证据
- 批准号:
23K18808 - 财政年份:2023
- 资助金额:
$ 1016.28万 - 项目类别:
Grant-in-Aid for Research Activity Start-up














{{item.name}}会员




